RxDoctor Payments Data

San Tso, DO

Family Medicine · Stockton, CANPI 1598876716

Payments from drug & device makers

$16,946in general payments, 2019–2025

Across 1,026 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • GSK$982
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$16,928100%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk99$1,608
AstraZeneca(2 entities)79$1,478
AbbVie(2 entities)103$1,460
Lilly USA, LLC80$1,304
Boehringer Ingelheim62$1,111
GSK70$982
Pfizer69$925
Merck40$676
Otsuka America Pharmaceutical, Inc.35$670
Johnson & Johnson56$665
Amgen(2 entities)32$604
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC31$468
Exact Sciences19$396
Sanofi-aventis U.S. LLC16$265
Bayer13$253
Novartis14$247
Vanda Pharmaceuticals Inc.10$232
Astellas Pharma US Inc12$210
Lundbeck LLC9$176
Biohaven Pharmaceutical Holding Company Ltd.10$171
Hologic Sales And Service, LLC8$169
Sunovion Pharmaceuticals Inc.15$168
Nestle Healthcare Nutrition Inc.6$154
Axsome Therapeutics, Inc.6$148
Biohaven Pharmaceuticals, Inc.8$141
Kowa Pharmaceuticals America, Inc.6$138
Aimmune Therapeutics, Inc.4$125
Teva Pharmaceuticals USA, Inc.8$118
Phathom Pharmaceuticals, Inc.5$115
Cranial Technologies, Inc8$113
Takeda Pharmaceuticals U.S.A., Inc.6$104
Mylan Specialty L.p.6$100
E.r. Squibb & Sons, L.L.C.5$99
Eisai Inc.4$85
Amarin Pharma, Inc.5$83
Abbott4$82
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$78
Baxter Healthcare4$70
Idorsia Pharmaceuticals US Inc4$68
Ironwood Pharmaceuticals, Inc5$68
Corcept Therapeutics3$66
Mannkind Corporation4$54
Electromed, Inc.3$54
Sanofi Pasteur Inc.3$53
Philips North America LLC2$48
Advanced Respiratory, Inc2$46
Sumitomo Pharma America, Inc.2$40
Mayne Pharma Commercial LLC2$38
Viatris Specialty LLC2$35
Boston Scientific1$29
Kyowa Kirin, Inc.1$26
Nabriva Therapeutics, PLC2$24
Sanofi1$22
Arbor Pharmaceuticals, Inc.1$19
Seqirus USA Inc1$18
Biogen1$18
Optos, Inc.1$17
Almatica Pharma LLC1$17
Verona Pharma, Inc.1$17
Assertio Therapeutics, Inc.1$17

How this compares

$16,946 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$157,075
Medicare patients
319
Services billed
1,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$206,085
JardianceEmpagliflozin59$79,146
RinvoqUpadacitinib11$66,997
FarxigaDapagliflozin Propanediol40$51,721
JanuviaSitagliptin Phosphate35$46,198
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$30,646
JanumetSitagliptin Phos/Metformin Hcl19$30,176
TradjentaLinagliptin26$28,189
MounjaroTirzepatide18$20,962
LinzessLinaclotide12$19,921
Breo ElliptaFluticasone/Vilanterol40$17,351
EliquisApixaban21$17,062
Nurtec OdtRimegepant Sulfate12$12,088
Tresiba Flextouch U-200Insulin Degludec19$10,005
Tresiba Flextouch U-100Insulin Degludec13$8,265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,608$206,085118 claims
Boehringer IngelheimJardiance, Tradjenta$1,111$107,33585 claims
AbbVieRinvoq, Linzess, Synthroid$1,460$89,19752 claims
MerckJanuvia, Janumet$676$76,37454 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$982$52,857100 claims
AstraZenecaFarxiga$1,478$51,72140 claims
PfizerEliquis, Nurtec Odt$925$29,14933 claims
Lilly USA, LLCMounjaro$1,304$20,96218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →